Allosteros Therapeutics, Inc.
United States
unknown
unknown
Stage
About
Allosteros Therapeutics was a drug discovery company developing selective small-molecule inhibitors of the Ca2+-dependent kinase CaMKII to address cardiovascular disease. Its CaMKII inhibitors demonstrated preclinical proof-of-concept for atrial fibrillation and ventricular arrhythmia by normalizing calcium homeostasis implicated in heart failure.
Explore Allosteros Therapeutics, Inc.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.